CONTEXT: Activation of the receptor for advanced glycation end products (RAGE) mediates cellular injury. Soluble forms of RAGE [soluble RAGE (sRAGE), endogenous secretory (esRAGE)] bind RAGE ligands, thereby preventing downstream signaling and damage. OBJECTIVES: The objective of the study was to characterize the changes in maternal serum, amniotic fluid, and cord blood soluble receptor for advanced glycation end products (sRAGE) during physiological gestation and to provide insight into mechanisms responsible for RAGE activation in preeclampsia. DESIGN AND SETTINGS: This was a cross-sectional study at a tertiary university hospital. PATIENTS: We studied 135 women in the following groups: nonpregnant controls (n = 16), healthy pregnant controls (n = 68), pregnant women with chronic hypertension (n = 13), or pregnant women with severe preeclampsia (sPE; n = 38). INTERVENTIONS AND MAIN OUTCOME MEASURES: sRAGE and esRAGE levels were evaluated in vivo by ELISA in maternal serum, amniotic fluid, and cord blood and in vitro after stimulation of the amniochorion and placental explants with lipopolysaccharide or xanthine/xanthine oxidase. Placenta and amniochorion were immunostained for RAGE. Real-time quantitative PCR measured RAGE mRNA. RESULTS: Pregnant women had significantly decreased serum sRAGE compared with nonpregnant subjects (P < 0.001). sPE women had higher serum and amniotic fluid sRAGE and esRAGE relative to those expected for gestational age (P < 0.001). Cord blood sRAGE remained unaffected by sPE. RAGE immunoreactivity and mRNA expression appeared elevated in the amniochorion of sPE women. Xanthine/xanthine oxidase (but not lipopolysaccharide) significantly up-regulated the release of sRAGE (P < 0.001) in the amniochorion explant system. CONCLUSIONS: Fetal membranes are a rich source of sRAGE. Elevated maternal serum and amniotic fluid sRAGE and esRAGE, paralleled by increased RAGE expression in the amniochorion, suggest activation of this system in sPE.
CONTEXT: Activation of the receptor for advanced glycation end products (RAGE) mediates cellular injury. Soluble forms of RAGE [soluble RAGE (sRAGE), endogenous secretory (esRAGE)] bind RAGE ligands, thereby preventing downstream signaling and damage. OBJECTIVES: The objective of the study was to characterize the changes in maternal serum, amniotic fluid, and cord blood soluble receptor for advanced glycation end products (sRAGE) during physiological gestation and to provide insight into mechanisms responsible for RAGE activation in preeclampsia. DESIGN AND SETTINGS: This was a cross-sectional study at a tertiary university hospital. PATIENTS: We studied 135 women in the following groups: nonpregnant controls (n = 16), healthy pregnant controls (n = 68), pregnant women with chronic hypertension (n = 13), or pregnant women with severe preeclampsia (sPE; n = 38). INTERVENTIONS AND MAIN OUTCOME MEASURES: sRAGE and esRAGE levels were evaluated in vivo by ELISA in maternal serum, amniotic fluid, and cord blood and in vitro after stimulation of the amniochorion and placental explants with lipopolysaccharide or xanthine/xanthine oxidase. Placenta and amniochorion were immunostained for RAGE. Real-time quantitative PCR measured RAGE mRNA. RESULTS: Pregnant women had significantly decreased serum sRAGE compared with nonpregnant subjects (P < 0.001). sPE women had higher serum and amniotic fluid sRAGE and esRAGE relative to those expected for gestational age (P < 0.001). Cord blood sRAGE remained unaffected by sPE. RAGE immunoreactivity and mRNA expression appeared elevated in the amniochorion of sPE women. Xanthine/xanthine oxidase (but not lipopolysaccharide) significantly up-regulated the release of sRAGE (P < 0.001) in the amniochorion explant system. CONCLUSIONS: Fetal membranes are a rich source of sRAGE. Elevated maternal serum and amniotic fluid sRAGE and esRAGE, paralleled by increased RAGE expression in the amniochorion, suggest activation of this system in sPE.
Authors: M Neeper; A M Schmidt; J Brett; S D Yan; F Wang; Y C Pan; K Elliston; D Stern; A Shaw Journal: J Biol Chem Date: 1992-07-25 Impact factor: 5.157
Authors: P Boor; P Celec; K Klenovicsová; B Vlková; T Szemes; G Minárik; J Turna; K Sebeková Journal: Clin Chim Acta Date: 2010-03-30 Impact factor: 3.786
Authors: Katherine R Millen; Catalin S Buhimschi; Guomao Zhao; Kara M Rood; Sammy Tabbah; Irina A Buhimschi Journal: Hypertension Date: 2018-04-23 Impact factor: 10.190
Authors: Hanaa K B Motawea; Maqsood A Chotani; Mehboob Ali; William Ackerman; Guomao Zhao; Amany A E Ahmed; Catalin S Buhimschi; Irina A Buhimschi Journal: Am J Pathol Date: 2018-09-29 Impact factor: 4.307
Authors: Y Yu; K F Hanssen; V Kalyanaraman; A Chirindel; A J Jenkins; A J Nankervis; P A Torjesen; H Scholz; T Henriksen; B Lorentzen; S K Garg; M K Menard; S M Hammad; J A Scardo; J R Stanley; M Wu; A Basu; C E Aston; T J Lyons Journal: BJOG Date: 2012-08-20 Impact factor: 6.531